Advair Diskus 250 [Fluticasone Propionate + Salmeterol inhalation powder 250mcg | 50mcg x 60 doses] CANADIAN PHARMACEUTICAL GRADE

Description

ADVAIR DISKUS 250 [FLUTICASONE PROPIONATE + SALMETEROL INHALATION POWDER 250MCG | 50MCG X 60 DOSES] – CANADIAN PHARMACEUTICAL GRADE RESEARCH COMPOUND

Advair Diskus 250 combines Fluticasone Propionate (250mcg) and Salmeterol Xinafoate (50mcg) in a dry powder inhalation format designed for research into corticosteroid receptor activity, adrenergic signaling, and pulmonary anti-inflammatory pathways.

Researchers employ this dual-compound system to study coordinated anti-inflammatory and bronchodilatory mechanisms, as well as the pharmacodynamic interplay between glucocorticoid receptor agonists and beta-2 receptor modulators.

Each sealed Diskus device provides 60 metered doses and is manufactured to Canadian pharmaceutical-grade standards. Independent testing confirms product integrity, potency, and consistency across batches.

Key experimental applications include pulmonary signaling analysis, steroid/adrenergic receptor modulation studies, and combination therapy modeling in controlled laboratory environments.

For research and educational purposes only. The customer assumes full responsibility for the proper handling and application of this product.